(NASDAQ: VTRS) Viatris's forecast annual revenue growth rate of 2.12% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 8.8%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.45%.
Viatris's revenue in 2026 is $14,737,300,000.On average, 12 Wall Street analysts forecast VTRS's revenue for 2026 to be $17,318,453,047,392, with the lowest VTRS revenue forecast at $16,573,017,576,656, and the highest VTRS revenue forecast at $18,011,053,338,384. On average, 12 Wall Street analysts forecast VTRS's revenue for 2027 to be $17,659,584,534,000, with the lowest VTRS revenue forecast at $16,764,832,250,944, and the highest VTRS revenue forecast at $18,484,272,774,352.
In 2028, VTRS is forecast to generate $18,031,727,973,936 in revenue, with the lowest revenue forecast at $16,791,249,840,816 and the highest revenue forecast at $19,117,146,340,416.